Background Poor adherence to treatment diminishes its individual and public health benefi t. Financial incentives, provided on the condition of treatment attendance, could address this problem. Injecting drug users are a high-risk group for hepatitis B virus (HBV) infection and transmission, but adherence to vaccination programmes is poor. We aimed to assess whether contingency management delivered in routine clinical practice increased the completion of HBV vaccination in individuals receiving opioid substitution therapy.
Introduction
Poor adherence to treatment is a widespread problem that reduces the individual and public benefi t from numerous health interventions. 1 For addiction, evidencebased treatments exist (eg, opioid substitution treatment), 2 but do not provide their full benefi t because of poor adherence and high progressive dropout. 3 Building on the behavioural principles of operant conditioning, contingency manage ment involves the systematic application of positive reinforcement 4 (use of fi nancial or material incentives) to promote adherence to treatment or behaviour consistent with treatment goals and thereby amplify the benefi ts of existing treatment. Substantial interest exists in the application of contingency management as an adjunct to treatments delivered in various contexts, 4 and particularly within treatment for addictions. 5 Strong evidence from the USA supports the eff ectiveness of contingency management to improve outcomes of existing addiction treatments. 6 However, the generalisability of these fi ndings might be restricted by the extensive use of specialist therapists employed solely to deliver contingency management, and its frequent assessment within specialist research centres. The UK National Institute for Health and Care Excellence (NICE) recommends that contingency management should be applied and assessed in routine clinical practice in the UK, 7, 8 and identifi es adherence to time-limited health interventions such as hepatitis B virus (HBV) vaccination 9 ,10 as a potential intervention target. However, despite international evidence for contingency management, in common with most other developed and developing health-care systems, the UK has no track record in this area. Hence the feasibility, acceptability, and clinical and cost-eff ectiveness of this intervention need to be assessed in routine drug-treatment settings.
11
HBV infection (and associated health sequelae) is a global health problem. 12 Injecting drug users are a major risk group for infection and transmission 13 and an important target population for vaccination. 14 In the UK, HBV infection aff ects about 22% of injecting drug users. 15 Clinical guidance recommends routine HBV vaccination be off ered to people receiving addiction treatment, 16 but although prison-based programmes have improved vaccination uptake in recent years, 17 a need remains to improve the uptake and completion of vaccination programmes off ered to people entering community treatment. 18 We aimed to assess the eff ectiveness of contingency management in promoting the completion of HBV vaccination in community drug-treatment settings, comparing the off er of fi xed and escalating incentives for on-time attendance at vaccinations with the off er of vaccination without incentive.
Methods

Study design and participants
In our cluster randomised trial, we enrolled participants at 12 National Health Service drug treatment clinics in the UK. All sites provided opioid substitution therapy and nurse-led blood-borne virus services. We trained clinic staff to deliver contingency management as part of routine care. In accordance with clinical guidelines, all sites off ered HBV vaccination to patients starting new treatment episodes according to a super-accelerated vaccination schedule (three injections on days 0, 7 and 21). 16, 19 Local clinical teams assessed eligibility of patients in participating services within the fi rst 2 months of a new period of opioid substitution therapy. Adults aged 18-65 years were eligible if they had previous, current, or future risk of injecting drug use and agreed to receive vaccination, participate in the trial, and provided written informed consent. Individuals were excluded if they were pregnant or breastfeeding or not clinically eligible to receive HBV vaccination (ie, previously received vaccination or had HBV infection).
The trial was reviewed by the North London Research Ethics Committee 2 and received a favourable ethical opinion on Sept 27, 2010 (reference 10/H0724/56).
Randomisation and masking
Randomisation was undertaken independently by the Kings Clinical Trials Unit (Institute of Psychiatry, King's College London, London, UK). Clusters were assigned to treatments with a random permuted blocks approach, with a block size of 3 in a 1:1:1 allocation ratio. Sites were randomly allocated to provide HBV vaccination without contingency management (treatment-as-usual group), HBV vaccination with fi xed-value incentive (fi xed group; service users received up to an aggregate total of £30, provided as a £10 voucher at each of three vaccinations), or HBV vaccination with contingency management of an incentive that increased in value (escalating group; participants received up to an aggregate total of £30 in vouchers, provided as a £5 voucher at fi rst vaccination visit, a £10 voucher at second vaccination visit, and a £15 voucher at third vaccination visit). In both contingency management groups, eligibility to receive a voucher was conditional on attendance at the appointment on time and compliance with the vaccination schedule as clinically indicated.
In most sites, vaccination was off ered to all patients whose clinical eligibility was established through a verbal assessment. However, some sites used blood tests to establish a patient's HBV antibody concentrations either before or during the vaccination schedule. Where this practice was followed, if the blood test showed the patient had suffi ciently high concentrations of antibodies, the service would either not start the vaccination schedule or would not continue with the vaccination schedule if it had been started. Because of the potential eff ect of this diff erence in practice on our primary outcome, randomisation was stratifi ed by whether sites undertook blood tests and acted upon the results within 7 days of the fi rst vaccination appointment (ie, before vaccination 2). Three of 12 sites undertook blood testing. An open-label design was used for this trial owing to the nature of the intervention; researchers, clinicians, and statistician were unmasked to treatment allocation.
Procedures
The vaccination schedule off ered in each site was identical apart from the absence or presence (and type) of fi nancial incentive. We used a super-accelerated vaccination schedule in accordance with best clinical practice as recommended by the UK Department of Health 16, 19 for use with injecting drug users or individuals at risk of injecting. These individuals are at high risk of contraction and transmission of the disease and should be immunised as rapidly as possible.
Patients completed a research interview before enrolment into the trial. The research interview assessed sociodemographic variables, drug and alcohol use, and drug treatment history (Opiate Treatment Index  20 and  Alcohol Use Disorders Identifi cation Test   21 ) and health status (EQ-5D 22 and Short Form-36 23 ). On conclusion of the interview, site treatment allocation was revealed and when relevant, scripted information was provided explaining eligibility for receipt of the fi nancial incentives. Patients were given a fi rst vaccination appointment (day 0) at least 24 h after enrolment. Attendance at the three HBV vaccination appointments was recorded for up to 3 months.
Nurses providing HBV vaccinations received training on trial procedures and, if working in an intervention site, the principles and practice of contingency management (panel 1). 5 All trial appointments were recorded as audio and a random sample of 40 recordings (stratifi ed by treatment allocation and fi rst or subsequent vaccination) were rated for adherence to the intervention protocol according to a bespoke measurement scale. We regarded good adherence as a score of at least 66% and poor adherence as a score of less than 33%.
Outcomes
The primary outcome was the completion of HBV vaccination within 28 days of the fi rst vaccination (day 0). Patients were defi ned as completers if they attended all scheduled, clinically relevant vaccination appointments, or attended but were not vaccinated because of existing immunity. We chose 28 days as the primary endpoint because this timeframe was consistent with some rescheduling of appointments by patients (permitted by our protocol if agreed in advance) and the occasional necessary rescheduling of appointments by clinics. Sensitivity analyses examined completion of the vaccination schedule with a strict defi nition of completer requiring ontime attendance at all relevant vaccination appointments, and a more relaxed defi nition requiring patients to complete all relevant vaccination appointments within 3 months.
We also recorded incidence of serious adverse events, which we assessed for seriousness and relatedness to vaccination.
Statistical analysis
We calculated the sample size to allow a separate comparison of treatment as usual versus fi xed and escalating contingency management approaches. No directly comparable data exist from which to base a power calculation, but we used data from a similar study 9 that compared contingency management with an outreach programme promoting completion of HBV vaccination that reported large diff erences (69% for the CM approach vs 23% for the outreach programme). The sample size was based on the assumption that the percentage of participants completing clinically relevant vaccination would increase from 23% in the treatment as usual conditions to 69% in the two contingency management conditions.
A randomised controlled trial would require an overall sample size of 29 participants per group to provide 90% power for a two-sided test at 5% signifi cance to detect a diff erence of completers of 69% in contingency management and 23% in treatment as usual (allowing 5% attrition). To account for possible cluster eff ects, we increased the sample size by an infl ation factor of 1·75, calculated on assumption of intraclass correlation of 0·05 on the basis of previous studies 24 with a planned 16 participants per cluster. This increase equated to 51 participants per intervention group, with at least three clusters per intervention needed to achieve 90% power. We therefore planned to trial each intervention in four clusters, with 16 participants per cluster (192 participants overall, 64 participants per trial intervention, and 12 clusters) because recruitment of 192 participants provides 90% power for a two-sided test at 5% signifi cance between each contingency management treatment versus treatment as usual. The study was also powered suffi ciently if the trial resulted in unequal cluster sizes based on an average of 16 per site with minimum cluster size of six and maximum of 26.
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The statistical analysis plan was approved by the trial steering and data monitoring committees. We regarded p<0·05 as signifi cant for all analyses. We analysed all data at the individual level, accounting for clustering at the site level and based on the intention-to-treat sample. We summarised continuous variables as mean (SD) and categorical variables as n (%). The unadjusted comparison of categorical variables was by Fisher's exact test. Our primary outcome analysis measured on-time attendance for vaccination and did not depend on post-intervention follow-up of the patient. Therefore, attrition contributed to our outcome measure and thus no outcome data would be regarded as missing.
For the primary analysis, we assessed the binary outcome completer status with a generalised estimating equation (GEE) to account for potential correlations of outcomes within sites, specifying an exchangeable correlation matrix. We adjusted the GEE logistic regression (specifying a binomial family and logit link) for trial group and the randomisation stratifi cation factor (blood test) with a fi xedeff ects approach. 26 We also calculated the number needed to treat (NNT) to achieve completer status.
In the sensitivity analyses, we recategorised data into the outcome completer status, adjusted for the two time assumptions. We analysed the binary outcomes within a GEE, specifying an exchangeable correlation matrix and adjusting the GEE logistic regression (with a binomial family and logit link) for trial group and the randomisation stratifi cation factor with a fi xed-eff ects approach. We
Panel 1: Training and supervision of nurses
All staff delivering hepatitis B virus (HBV) vaccination with or without contingency management were registered nurses working within substance misuse services and employed as either keyworkers (providing HBV vaccinations as part of their role) or specialist nurses providing a range of blood-borne virus interventions (including HBV vaccinations). All nurses had previously received training in provision of HBV vaccinations.
Nurses responsible for provision of HBV vaccinations were instructed on trial procedures and those working in sites allocated to contingency management also received a bespoke 1 day training course in the principles and practice of contingency management, including simulation and role play from psychologists on the research team. A training manual was written by the research team and provided to all nurses.
All HBV vaccination appointments were recorded as audio. Supervision (either face-to-face or telephone) was provided to nurses working in sites allocated to contingency management throughout the trial by a psychologist from the research team after review of selected audio recordings. 40 audio recordings were reviewed and rated for adherence to the contingency management protocol by use of a specifi cally developed adherence measure. 
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between Feb 1, 2011, and Jan 31, 2012, we randomly allocated 12 services (clusters) to three treatment groups (fi gure 1). 210 (23%) of 914 patients screened for eligibility consented to enrolment (fi gure 1). Study participants were broadly representative of patients entering opioid substitution therapy in the UK, 27 in that they were mostly men (167 [80%] participants) and white (158 [75%] participants) with a mean age of 36·2 years (SD 8·2). The three study groups were well matched on key (table 2) . At the second appointment, about a third of participants in the treatment as usual group attended compared with nearly two-thirds in the contingency management groups (table 2) . At the third vaccination appointment, only a fi fth of patients in the treatment as usual group attended compared with half of participants in the contingency management groups (table 2) . Figures 2 and 3 show the proportions of the expected attendees who did attend (ie, individuals off ered each successive vaccination as opposed to the total enrolled population), showing the increased attrition in the treatment as usual group at all timepoints. The highest rate of attrition in all treatment groups occurred at the fi rst vaccination and attrition in the control group was higher than in both contingency management conditions at vaccinations 2 and 3 even in patients who attended vaccination 1 in the absence of reinforcement (fi gure 3).
Of participants in the contingency management groups who attended vaccinations, at least 80% did so on time and received clinically appropriate vaccinations at each of the three appointments (ie, achieved the target behaviour; table 2). By contrast, only 50-65% of the lower overall numbers of participants in the treatment as usual group who attended appointments did so on time (table 2) .
Most attendances resulted in vaccination. 13 participants attended appointments but did not have a clinical need for (further) vaccination because they were identifi ed as having immunity (three in the treatment-as-usual group, four in the fi xed contingency management group, and six in the escalating contingency management group). All were regarded as completers in our outcome analyses. Four participants attended but refused vaccination (two in Data are n (%) or n/n (%). *For vaccination 1 the base date (day 0) was defi ned as the fi rst appointment date off ered to the participant unless rescheduled by the clinic or the participant (but only in advance and with the agreement of the nurse); under these circumstances, the rescheduled appointment was regarded as day 0. Thus, any vaccinations given after day 0 will have been given because the patient did not attend the fi rst appointment off ered and then received the vaccination at a later date. †Participants who attended the vaccination appointment on the scheduled date and time, including those who attended at a date and time rescheduled by the client in advance and with the agreement of the clinic. ‡Participants who attended on the appointment date but outside the appointed timeframe, or on a rescheduled date made after a previous non-attendance of one or more appointments. §Participants who achieved target behaviour (ie, attended the appointment on time and either received the vaccination or were not vaccinated because they had established immunity). ¶Participants non-compliant with appointment schedule required to receive vaccination describes participants who attended but were not on-time, refused vaccination, or were required to attend on a subsequent day (eg, for clinical reasons) and did not do so. Table 2 : Participant fl ow through the vaccination schedule the treatment as usual group, two in the fi xed contingency management group).
Incentives were given in error when the target behaviour was not achieved in ten (4%) of 271 appointments in the contingency management groups. These errors mostly occurred when participants received a vaccination but had not attended on time. However, adherence, expressed as a mean percentage of the total adherence score was modest at 53%. Of the 40 audio recordings assessed, 13 (33%) were rated as good adherence and 13 (33%) were rated as poor adherence. Poor adherence scores were mainly due to failure to explain the schedule, off er suffi cient praise, or check that participants understood the schedule. Tapes were independently rated by two reviewers and good interrater reliability was achieved (intraclass correlation 0·873, 95% CI 0·773−0·930). Table 3 shows the proportion of participants in each group who completed the vaccination schedule in 28 days, the number of participants classifi ed as completers who were identifi ed as immune and received up to three vaccinations (three in the treatment-as-usual group, four in the fi xed contingency management group, and fi ve in the escalating contingency management group), and the results of the GEE modelling.
In the primary outcome analysis, we noted signifi cantly increased completion rates for HBV vaccination in both contingency management groups compared with treatment as usual (table 3). Participants in both contingency management groups were more likely to complete the vaccination schedule within 28 days than were those in the treatment as usual condition (table 3) . The intraclass correlation coeffi cient for the site clustering was estimated at 0·097. Figure 2 shows the predictive probability from the fully adjusted GEE modelling of completion of vaccination within each group and confi rms that the diff erences in vaccination completion rates were signifi cant. Unadjusted χ² statistics show diff erences in the completion rates between the fi xed contingency management group and the treatment as usual group (35 of 78 in the fi xed group vs six of 67 in the treatment as usual group; χ² 22·9, p<0·0001) and escalating contingency management and treatment as usual (32 of 65 participants in the escalating group vs six of 67 participants in the treatment as usual group; χ² 26·1, p<0·0001).
Compared with treatment as usual, the NNT was 2·78 (2·05-4·36) for fi xed contingency management and 2·48 (95% CI 1·84-3·80) for escalating contingency management.
Our fi rst sensitivity analyses assessed whether contingency management was associated with increased full compliance with the vaccination schedule, through comparison of the proportions of participants who completed their vaccinations with the strict defi nition of completer that required on-time attendance at all relevant vaccination appointments. This measure might thus be regarded as a proxy for improved clinic effi ciency. We noted substantially improved rates of completion for both contingency management groups versus treatment as usual (table 3, fi gure 2) Our second sensitivity analysis assessed whether the benefi t of contingency management remained if a longer follow-up period was used, through comparison of the proportions of participants who completed their vaccinations with a relaxed defi nition of completer that required participants to complete all relevant vaccination appointments within 3 months of recruitment. In this analysis, completion rates were higher in all treatment groups, with the proportion of completers in the treatment as usual group increasing to 25% (17 of 67 participants). However, completion rates remained highest in the contingency management groups (table 3) . Three participants died in the treatment as usual group (one cardiac arrest, one deep vein thrombosis, and one unknown cause in a patient not administered vaccine). Other serious adverse events were one case of pneumonia in the treatment as usual group and one psychiatric admission in a participant in the fi xed contingency management group. No other serious adverse events were reported, and none was regarded as related to treatment. We noted no association between serious adverse events and trial condition (Fisher's exact test p=0·50).
Discussion
NICE has identifi ed contingency management as a behavioural intervention with the potential to increase adherence to physical health interventions amongst drug users. 7, 8 In our study of HBV vaccination in routine clinical practice, we noted improved rates of completion of vaccination and adherence to appointment schedules when the off er of vaccination was combined with contingency management with fi nancial incentives (panel 2).
That incentives increase adherence is unremarkable, but the size of increase we noted was striking. The fi ndings of our health economic analysis are ongoing and will be presented elsewhere but, notably, increased vaccination was associated with relatively modest levels of fi nancial reinforcement. Our primary outcome measure was completion of the 21 day vaccination schedule within 28 days. We noted a signifi cant advantage with each of the contingency management reinforcement conditions (49% and 45%) compared with treatment as usual (9%). In addition to the increased rate of completion, participants receiving contingency management mostly attend appointments on time, which off ers providers an additional advantage in terms of effi cient use of resources.
In our primary analysis, the completion rate with treatment as usual was very low and merits comment. Ideally, we would be able to compare our fi ndings with data from routine practice. However, no information is available at present about vaccination completion rates as a proportion of patients off ered opioid substitution therapy or compliance with vaccination schedules. The completion rate in our treatment as usual group seems substantially worse than that recorded in injecting drug users in other settings (notably prison vaccination programmes), 17 but comparison with data from such settings needs to be made with caution. The completion rate in our sensitivity analysis, which included vaccination up to 3 months, was substantially higher than it was in the primary analysis (25% vs 9%) and was close to the completion rates noted by Seal and colleagues (23%). 9 This analysis probably provides a better comparison with routine completion rates. Nevertheless, even with this 3 month timeframe, the benefi t of contingency management over treatment as usual remained substantial, with completion rates exceeding 50% in both contingency management groups.
Our study was not powered to examine diff erences between the two contingency management conditions but the gains achieved by each of the two schedules were much the same (odds ratio 12·1 and NNT of 2·78 for fi xed contingency management and odds ratio 13·9 for escalating contingency management and NNT of 2·48). Although clinician adherence to some aspects of the intervention protocol was modest (mainly failure to explain the schedule, off er suffi cient praise, or check understanding of the participants), the incentive was given correctly in 261 (96%) of 271 appointments. One interpretation of these fi ndings is that these poorly delivered aspects of the protocol might be less powerful infl uences on outcome than the tangible fi nancial reinforcement which was invariably delivered appropriately. We are also mindful that, despite the high Data are n (%), odds ratio (SE, 95% CI; p value), or mean (SD). *Includes one participant whose immunity was established after receipt of the second vaccination; the participant attended vaccination 3 but was informed of their immunity status and not given a third vaccination. †From the fully adjusted generalised estimating equation model, controlling for the blood test status and allowing for site at the cluster level. ‡For vaccination 1 the base date (day 0) was defi ned as the fi rst appointment date off ered to the participant unless rescheduled by the clinic or the participant (but only in advance and with the agreement of the nurse); under these circumstances, the rescheduled appointment was regarded as day 0. Thus, any vaccinations given after day 0 will have been given because the patient did not attend the fi rst appointment off ered and then receiving the vaccination at a later date. §The base time was used for the calculation of the time to vaccination 2 and 3. odds ratios, only about half the participants completed the vaccination schedule in the contingency management groups. Elsewhere, we will present the results of secondary analyses in which clinician adherence, treatment fi delity, and competence to behavioural principles are included as predictors of outcome. Our fi ndings suggests that contingency management for HBV vaccination is an eff ective and robust interventionirrespective of schedule-despite variation in staff adherence to some aspects of the reinforcement protocol. Three main conclusions can be drawn from our fi ndings.
First, we identifi ed a powerful benefi cial eff ect of contingency management in relation to a time-limited physical health intervention, which nevertheless has enduring benefi t. 36 Our fi ndings were obtained in realworld clinical circumstances, and therefore support the conclusions of NICE 7, 8 that this adjunctive technique should be routinely applied to increase the individual and public benefi t of vaccination programmes in drugtreatment settings. The low NNT and high odds ratios should attract the close attention of public health practitioners and clinicians working in the fi eld. These fi ndings might also have relevance to other areas of clinical practice in which clinical and public health benefi t could be achieved by incentivised improvement of treatment adherence in the short-term (eg, early antenatal care or tuberculosis testing).
Second, although diff erences in attrition at fi rst and subsequent vaccinations might attract some further debate and analysis, attrition was highest in the control arm at each vaccination. Our interpretation of these data is that (modest) reinforcement at each vaccination is probably necessary and prudent to achieve the clinically signifi cant health gains that are dependent on compliance with the full vaccination schedule. We would caution against too much further research focus on the precise schedule and instead we recommend concentrating energies on implementation.
Third, a strong case now exists for further rigorous assessment of contingency management in the UK for other areas of health-care provision. Investigators working in other clinical settings in which the patient and public health benefi t of current treatments would be enhanced by measures that improve compliance could benefi t from our fi ndings. Within the specialty of substance misuse, attention should now shift to more challenging areas of behaviour change (eg, reduction in illicit drug use), 7, 8 in which long-term robustness of the change is necessary for any health benefi t to be maintained.
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Panel 2: Research in context
Systematic review Evidence increasingly supports the eff ectiveness of contingency management for improvement of outcomes of drug users receiving substance misuse treatment. NICE 7, 8 identifi es that contingency management can directly target the desired behaviour change (eg, drug abstinence) or can work synergistically by targeting intermediate behaviours (eg, attendance or medication adherence): two major meta-analyses report eff ectiveness of contingency management in reducing drug use. 6, 28 Use of contingency management for time-limited interventions to produce irreversible health benefi ts (eg, hepatitis B virus [HBV] vaccination) was mooted by NICE 7, 8 but has received little attention in contingency management research; no meta-analysis has been published. Likewise for attention to physical comorbidities, apart from studies of contingency management to reinforce attendance for tuberculosis testing, 29 adherence to tuberculosis medication, [29] [30] [31] and to antiretroviral treatment for HIV. 32 In addition to small observational studies 33, 34 reporting increased uptake and completion of HBV vaccination associated with provision of fi nancial incentives to injecting drug users, there have been three randomised controlled trials examining contingency management targeted specifi cally at HBV vaccinations. One trial, 9 despite modest sample size (n=96), found contingency management (monthly monetary incentives) was signifi cantly more eff ective than an outreach programme (weekly contact with outreach worker) in achieving completion of HBV vaccination within 6 months (69% vs 23%). 9 A second trial 10 found contingency management (prize incentives) more successful than no contingency management with non-signifi cantly increased attendance of weekly sessions (82% vs 64%), increased compliance with all injections (77% vs 46%) and signifi cantly more injections received on the originally scheduled day (74% vs 51%). 10 A third randomised controlled trial, 35 from Australia, found monetary incentives (vouchers) more eff ective than no contingency management for completion of three-dose HBV vaccination (days 0, 7, 21) by injecting drug users. Monetary incentives not only improved compliance with HBV vaccination but also frequently achieved this within specifi ed appointment times.
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Interpretation
The fi ndings from our properly powered trial accord with previous studies, providing compelling evidence that contingency management signifi cantly improves completion of the three-injection vaccination schedule, so that approximately half of patients complete vaccination as scheduled. Further work is now required to refi ne the contingency management method to improve further the capture and completion of these vaccination schedules.
